[111in]-fpi-2058

Gastric Cancer

3B Pharmaceuticals GmbHradiopharmaceuticalPhase 1Active

C

37/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 65/ 100

Competitive context

282 Active assets in the Gastric Cancer cohort.

Asset / Sponsor	Phase	Rating
Rivoceranib Jiangsu Hansoh Pharmaceutical Co., Ltd.	Phase 4	BBB
FLUOROURACILUM I-Mab Biopharma US Limited	Phase 4	BB
Eloxatin Qilu Pharmaceutical Co., Ltd.	Phase 3	BB
Irinotecan Shenzhen Xinhe Biomedical	Phase 4	BB
Pembrolizumab Eikon Therapeutics	Phase 3	BB

View all 50 →

Same molecule, other indications

[111in]-fpi-2058 is also rated in:

NTSR1 Expressing Solid TumoursDormant

CC

Indicative ·

43 / 100

prostate neuroendocrine neoplasmDormant

CC

Indicative ·

43 / 100

head and neck squamous cell carcinomaDormant

CC

Indicative ·

41 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.